What is B. Riley’s Forecast for BCYC Q1 Earnings?

Bicycle Therapeutics plc (NASDAQ:BCYC) – Equities researchers at B. Riley issued their Q1 2025 earnings estimates for Bicycle Therapeutics in a report released on Monday, March 3rd. B. Riley analyst K. Patel expects that the company will post earnings per share of ($0.87) for the quarter. B. Riley has a “Neutral” rating and a $17.00 price objective on the stock. The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.06) per share. B. Riley also issued estimates for Bicycle Therapeutics’ Q2 2025 earnings at ($0.91) EPS and Q3 2025 earnings at ($0.96) EPS.

Several other analysts also recently issued reports on the stock. Stephens reaffirmed an “equal weight” rating and issued a $15.00 price objective on shares of Bicycle Therapeutics in a research report on Wednesday, January 22nd. JMP Securities reduced their target price on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research note on Wednesday, December 18th. HC Wainwright reiterated a “buy” rating and set a $33.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $30.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Bicycle Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $29.14.

Bicycle Therapeutics Stock Down 3.2 %

Shares of NASDAQ:BCYC opened at $10.14 on Tuesday. Bicycle Therapeutics has a 52-week low of $10.07 and a 52-week high of $28.67. The company has a 50 day moving average of $13.11 and a two-hundred day moving average of $19.19. The company has a market capitalization of $700.13 million, a price-to-earnings ratio of -3.08 and a beta of 1.12.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.10. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.47 million. During the same quarter last year, the company earned ($1.16) earnings per share. Bicycle Therapeutics’s revenue for the quarter was down 30.2% on a year-over-year basis.

Insider Buying and Selling

In related news, CAO Travis Alvin Thompson sold 2,686 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $15.00, for a total transaction of $40,290.00. Following the transaction, the chief accounting officer now directly owns 32,146 shares in the company, valued at $482,190. This trade represents a 7.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bros. Advisors Lp Baker acquired 985,397 shares of Bicycle Therapeutics stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average price of $13.76 per share, for a total transaction of $13,559,062.72. Following the completion of the purchase, the director now directly owns 9,537,643 shares of the company’s stock, valued at $131,237,967.68. The trade was a 11.52 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 27,677 shares of company stock worth $392,413 over the last ninety days. 8.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

Several large investors have recently added to or reduced their stakes in BCYC. Assetmark Inc. acquired a new stake in Bicycle Therapeutics in the third quarter worth $34,000. Barclays PLC increased its position in Bicycle Therapeutics by 878.3% in the fourth quarter. Barclays PLC now owns 2,612 shares of the company’s stock worth $37,000 after buying an additional 2,345 shares during the period. Avior Wealth Management LLC acquired a new stake in Bicycle Therapeutics in the fourth quarter worth $57,000. China Universal Asset Management Co. Ltd. increased its position in Bicycle Therapeutics by 30.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company’s stock worth $131,000 after buying an additional 2,191 shares during the period. Finally, JPMorgan Chase & Co. increased its position in Bicycle Therapeutics by 26.8% in the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock worth $191,000 after buying an additional 1,782 shares during the period. 86.15% of the stock is owned by institutional investors and hedge funds.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.